Diary - News
All news ELSALYS BIOTECH acquires from JAZZ PHARMACEUTICALS the worldwide rights of LEUKOTAC®
LEUKOTAC® is an immunotherapy antibody with clinical benefits in steroid-resistant acute Graft-versus-Host Disease
Lyon, FRANCE, October 12, 2017, ELSALYS BIOTECH, a new player in immuno-oncology, has acquired from JAZZ PHARMACEUTICALS the development and commercialization rights of LEUKOTAC® (inolimomab), a monoclonal antibody that has recently demonstrated its clinical superiority in the treatment of Steroid-Resistant acute Graft-versus-Host Disease (steroid-resistant aGvHD), an orphan disease with very poor prognosis.
Read the press release